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Cancer is the leading cause of death for persons under the age of
85. There have been tremendous advances in recent years in our
understanding of both the environmental causes of many cancers
and the molecular perturbations from which they arise, As cancer
is a collection of diseases many of these environmental and mo
lecular causes may be more important for one form of the disease
than another. A number of proteins have been identified as either
potential cancer chemotherapy targets or as molecular markers of
cancer progression. Because cancer can arise from a variety of
molecular pathologies it is unlikely that there will be a single silver
bullet that defeats all forms of the disease and it is important that we
continue to identify potential molecular targets. I here describe one
such new target called PEA-IS (and also named variously PED-IS.
MAT-I or PED/PEA- IS). PEA-IS can affect both cell survival and
proliferation and is overexpressed in many cancer cells including
those of breast cancer, glioma, and squamous carcinoma.
PEA-I 5 Structure and Function
PEA-IS was independently cloned using four very different ap
proaches. It was originally identified by Chneiweiss and colleagues
as a IS kilodalton, Phosphoprotein that is Enriched in Astrocytes
(hence the name PEA-I 5)2, Dr. Chneiweiss went on to clone the
cDNA corresponding to PEA-IS using biochemical methods. Al
ternatively Nandi and colleagues cloned a portion of the message
encoding PEA- 15 (which they then called MAT-I> by screening
expression libraries for their ability to transform mouse mammary
cells. This provided the first suggestion that PEA-IS might affect
oncogenesis. Subsequently Beguinot and colleagues used differential
display methods to clone PEA- IS (which they then called PED- IS> as
a phosphoprotein that is overexpressed in muscle from patients with
type II diabetes4. In this work they report that PEA-IS expression
inhibits insulin—stimulated glucose transport and may therefore be
involved in the development of type II diabetes. Finally, in collabo
ration with Mark Ginsberg and others, I isolated PEA-IS by using
expression cloning to identify proteins that block 1-1—Ras signaling5.
H-Ras is mutated in many different tumors and I therefore expected
that proteins that regulate H—Ras may also affect the development.
progression or pathology of some cancer cells,
PEA-IS is most highly expressed in the nervous system with
particularly high levels in asirocytes and neurons of the hippocam—
pus. It is also expressed in lymphocytes and cell lines derived
from gliomas, astrocvtomas, and breast cancers. Indeed PEA—IS
is reported to he overexpressed in some gliomas and breast cancer
cell lines compared to normal cells from these tissues7. PEA— IS is
phosphorylated at two sites by kinases including Protein Kinase C
serine 10$). calcium calmodulin kinase II, and Akt (both at serine
116). The message is alternatively’ spliced in the non—coding region
(3’UTR) and ubiquitously expressed in every tissue examined thus
far. However protein expression appears to he more confined, This
suggests that PEA-IS translation may he regulated. Structurally
PEA-IS consists of a death effector domain (DED) that corresponds
to the first 80 of its 130 amino acids (Figure 1). These DEDs have
been associated with proteins that regulate programmed cell death
or apoptosis
PEA-IS Binding Partners
PEA-IS is reported to bind several distinct proteins. These include
protems that regulate apoptosis. transcription, and proliferation.
PEA- IS is reported to bind to FADD via its DED7, FADI) is a
pro—apoptotic linker protein that activates apoptosis by binding to
the Fas receptor via its Death Domain (1)1)) at the plasma membrane
in response to receptor binding to ligand’4. This results in FADD
recruitment, aggregation and activation of caspases 8 or 10. The
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auto-actix ated spases then cleas e and activate other caspases that
cause the death of the cell bs degrading cellular proteins. PEA—
15 binding to FADI) is reported to block the abilit of FADD to
recruit and aeerceale the caspases. Two of these reports showed
direct binding of PEA- I 5 to E.ADD and! or caspase S while one
report found no such nteraction. Subsequentlx. recruitment to
FADD in the death initiation signaling complex DISC was shown
requii-e phosphor\ anon of PEA-IS and to he affected h\ PKC
phosphor\ lotion at sen tie 04 It rentat ns to be determined it
phosphor lation of PEA— IS alters its binding to FADF), however this
is strongh suggested. Hence tile discrepanc\ in the literature ma
he due to differences in the phosphors lation state of PEA-IS,
Akt is a serineiihreonne kinase that iransduces both proliferative
and surs ival signals AD hinds to PEA—IS and phosphorylates it at
serine 11 (C’. Moreover phosphorylation at this site increases the
anti—apoptotic action of PEA— I S perhaps by increasing its recruitment
to the DISC. Onii!HtrA2 is a pro—apoptotic mitochondrial serine
protease’ that hinds the DEl) of PEA—I 5w, It is reported to promote
apoptosis upon release from the mitochondria in part by reducing
cellular levels of PEA- I 5 and hence removing its anti—apoptotic
influence. Orni/HtrA2 also acts by degrading other proteins called
inhibitors of apoptosis (lAPs) such as XIAPL, Omi!HtrA2
ditionall proposed to he involved in cancer as a result of its role
in apoptosis.
PEA—IS also hinds ti the MAP kinase ERK l!22 at the Carhoxy—
Terminal tail with some contribution by amino acids of the DED.
ERK has multiple substrates and can regulate transcription, prolifera
tion. apoptosis and cell adhesionZ. PEA—IS hinds the MAP kinase
insert region of ERK . This is a legion that varies significantly
between different MAP kmases and this likely explains why PEA
lS does not bind other MAP kinases. PEA-IS binding to ERK
retains ERK in the c loplasm e en upon aclix anon of’ ERK. Man
ERK substrates are nuclear such as the lranseripf ion factor ELK
I and ERK nuclear translocation is required Ion ERK—dependent
transcription. for example. Hence PEA— IS i’etention of ERK m the
cytoplasm poteniiail\ alters the transcriptional fingerprint ol cells
stimulated by growth factors such as LOP. Indeed we have reported
that O\ erexpression of PEA- IS blocks ERK activation of ELK-I
and can also block (‘REI-3 mediated transcription. Two separate
nicehanisms by w hich PE.-\— IS inaimains ERK in the cvtoplasni
have been proposed. One is that PEA— IS has a nuclear export
signal (\ESt and can hind both active and inactise ERK and carry
them out of the nucleus. A second i’ that PEA- 15 binding to ERK
interferes with ER Ks’ abi I it to bind to the nucleopor ins of nuclear
pole complex and enter the nucleus:. It icmain’ unclear which is
the predominant mechanism. Knockout of PEA— IS causes increased
ERK localitation to the nucleus and results in increas-’d prolitera
tiOtt ifl Jstioc\ tcs. Rc-expresion ot PEA- IS returns pt’olifet’ation to
ttornial Ics els PEA- IS influence 0! proliferation provtdes a dtrect
was h\ a hich PP -\- 5 could modulate cancer cell protiteration and
tumor gi’oa th.
Rsk2 is a substrate of ERK and a kinase that can activate transcrip
tion and regulate apoptosis . Itcontains two kinasedomainsand can
also hittd directl\ to ERK at its carhox\ I terminal sequence. Rsk2
is sttggested to bind soIel to the Carhoxyl-terminal tail of PEA- IS
hut the exact site is tiot \ct detertuttied . PEA-I S overexpression
ifiLcts Rck2 in tin It tfa itnc w is is tt cIos ERR It prevunts
Rsk2 ti’anslocation or accumulation m tile nucleus and perhaps as a
result blocks Rsk2—dependent activatitm of’ the transcription factor
CREW’. PE.—\— IS appears to hind equalls well to both active and
inactive Rsk2. It is enticing to suggest that since Rsk2 is a substrate
for ER K and that PEA— IS Nnds to both, that PEA— IS may enhance
on impair ERK aetis atioti of’ Rsk2. Rsk2 is also reoonmed to enhance
actt\ atioti ot’estnogen receptor alpha- and this may pros idea ntecha
nism whereh PEA—I S could i nlluence breast cancer pnogressii in.
FinalE PE:\— IS also can hind pliospholipase Dl and 1)2 PLF) atia
smahiliic their expression- . P1.1) is a membrane associated lipase
that catal /es the prodLiction of phosphafidic acid and is reported to
be in oh ed in ntan signaling pwcesses including ERR activation.
apoptosis and glucose transport-’ . PEE) hinds to PEA-iS at a site
consisting of sequence l’i’om both the DEE) and the carhoxyl-ter
minal tail: . (‘o-expression of PEA IS with PLD1 increased PLDI
expression les eI and activity. It is intriguing that PLI) functions so
closel resemble those of PEA- 15. This may indicate a Iieretohre
undiscovered intendepetidence of these proteins.
Therefore PEA- IS interacts with a broad arra of proteins that can
he generally gi’ouped as either those involved in apoptosis. those
involved in transcription. or those involved in both. Indeed the one
common function attributed to all these proteins is that they- regulate
cell survival, Another protein with similarly diverse interactions is
14-3-3. 14-3-3 acts in part as a kind of’ protein sink, holding some
proteins inactive until they are needed-. It is possible that PEA— IS
may perform an analogous function. blocking some activities of its
binding partners when expressed. It is therefore very important to
determine how these interact ions may he regulated.
Evidence of a role for PEA-15 in Oncogenesis
The first evidence that PEA-IS mig lit play some role in cancer was
found when it was identified as a mouse mammary transforrnin
gene. In these experiments acDNA libnar\ ‘sas derived from mouse
mamman\ tumors induced h lithium. The eDNA hibnar\ was then
screened ton clones that neoplasticall ii’ansiom-med a culture ccii
line 1 >IH 3[3i. The\ showed that PEA— IS is normall expressed
in maul man\ eel Is a id that it was i wenexpressed m their Ii th iti mu
induced ftimins. These ins estigators subsequently identified the
Human on hi I ig of PEA — I S and demonstrated that in thi’ee hu utan
breast cancer cell lines t WE- It). T47-I). and MDA-\I13-23 I) PEA
lS message showed a 10- lold ovenexpression compared to pniman
normal human breast epithelial cells’ : How ever the open neadine
flame the’ mnitiaIl focused on was a s hom’t region of the mnR\A that
is downstream of the region encoding PE -\— IS. We ittdependcntlv
confirmed that \I-\T I niR\A does cause transtormatmon however
ni the same es.pernnents a lien we expi’ess an tiiR\ eomltaiimmia
only the coding region of PE.-\— IS. we see no traustonniatton data
not show ii. [fence the transforming capabilmv must reside m the
lange and highl\ cotisers ed 3’ LTR. Natidi and colleagues further
shosved that the PE \- I 5 itiR’s.\ is extremcl tahIe amid that theic are
differences in the expt’essiun ofthe alternatively spliced isoformns of
die PEA- IS mR -\ between mouse mammary epithelial cell lines -
Ther therefore prop se that the 3’ LTR may he a rihoregulator in
inatuinam\ tutiionigeiiesis. This hr pothesis has yet to he tested.
-\n alter nat is e ‘cries of expermients by- Hao atid colleagues sug
gest that PE-\- IS mar he important in glioma cells, They found that
glionia cell lines m’esistant to TRAH, itiduced apoptosis expressed 2
7g
fold more PEA— IS than TRAI L sensitive lines’. \Ioreos en trcms— References
fection of PEA- IS into the TRAIL sensitive lines rendered them
resistant to apoptosis. Reducing PEA—IS levels in TRAIL resistant
lines simi larl\ rendered them sensitive u i TRAIL induced apoptosi 5.
These data support the hypothesis that PEA- IS prevents TRAIL
induced apoptosis in these glioma cell lines. This anti—apoptotic
function was dependent on PKC phosphor’vlation. These results
are reminiscent of those of Chneiweiss and colleagues w ho found
that astrocytes derived from mice lacking the PEA— 15 gene were
more sensitis e to TNF—induced apoptosis than astroe\ tes from
nornial wild t\ pe mice Ii ss as -ubsequentl reported that onE
PEA—IS phosphor’olated at both sennes could be recruited to the
death inducing sig’nalino coniplex at the plasma membrane where
it could function to pres cut apoptosis. These results provide hope
that targeting PEA— 15 in gliomas (and perhaps other cancers) may
renderthe eancereells more sensitive to elimination when combined
with other chemotherapies.
There has e been other tindines that also suggest PEA— IS ma\
be important in the des elopment or progression of some cancers.
Studies using differential gene expression to identify changes in
gene expression in a squamous carcinoma model found that PEA—
15 was one of the genes that is upregulated30.Finally. PE.\- IS has
been reported to block sionaling from the knoss ii oncogene Ras’ -
and to pro ote Ras-mediated senescence. Since Ras transforms
cells and senescence prevents the transforming effect these studies
support the possibility that PEA-IS can act as a tumor suppressor.
This hypothesis is in conflict with that described above. Hosv can
PEA- IS both suppress tuniorigenesis by block
ing Ras and enhance tuniorigenesis by blocking
apoptosis. \-Ve do not ci has e an ansss er to
this question. It may be that whether PEA- IS
acts as a tumor suppressor or tumor promoter
depends on whether Ras activity is altered in
a given cancer cell. It is important to address
this issue in deternn ni no whether PEA— I S is
a viable drug target.
Conclusions
PEA- IS is reported to prevent cell death
limit cell proliferation—, alter trailserip—
tion , and activate cell adhesion’. All
of these es ents has e been implicated in the
torniation, progression and metastasis of
tumors. PEA- I S may therefore he a nexus at
which multiple cancer cell pathologies can he
targeted. Moreover iiiee PE.-\- I S has a sery
limited expression piofi Ic hut is os ereispressed
in man tumors it m;i\ be an ideal target for
drug design.
For more intormation on the Cancer Research
Center of Hass an. please x isit our web site at
wws’ crc h.org.
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MEDICAL AND DENTAL OFFICE SPACE AVAILABLE
Address:0 ST. FRANCIS MEDICAL CENTER 2228 Liliha Street -2228 LilihaStreet
Description:
Conveniently located medical
and dental office units close to
town and major medical centers.
Competitive rates. Access to
laboratory services, MRI, CT, PET,
Imaging services, cardiac cath
lab, outpatient pharmacy, and
other hospital services. Patient
parking.
Features:
Physician Time Share Office Space
a Centrally lotated
a Patiest exam roams
a Consultation rooms
a Medical Assistant
Medical Office Building Space
• CAM includes:
Electrixity, A/C.
Janitorial, Security.
Waturi Insurance,
Real Praperty Tax.
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Are you worried about the COST of your
medical malpractice coverage?
Over the last four years, 44% of all new HAPI members converted their coverage
to us from a previous carrier. Many of them saved 30%-50% on their medical
malpractice coverage costs upon joining HAPI.
Started 27 years ago. HAPI is Hawaiis
first physician-owned medical malprac
tice coverage provider.
New members, who need fully mature retroactive coverage, could save $4,000-
$30000 annually, depending on their specialty.
To learn more about HAP! and the cost
savings it may offer you. call Jovanka
Ijacic. our Membership Specialist.
Started 27 years ago, HAPI was formed by physicians to make certain that medical mal
practice coverage would be available to Hawaii physicians. Today. almost three decades
later. HAPI continues to be a financially secure, affordable plan for Hawaii’s physicians.
There is no profit motive at HAPI. Savings are passed on to our members. With a strictly
local presence, we use all of our funds to protect Hawaii’s doctors only.
HAPIs Physicians Indemnity Plan
735 Bishop Street. Suite 311.
Honolulu, HI 96813
808-538-1908
www.hapihawaii.com
In two separate surveys, conducted in 1998 and in 2002, we asked our members if they
would refer a colleague to HAPI. In both surveys, 100% said “YES.”
80
